추천 제품
분석
99%
양식
foil
제조업체/상표
Goodfellow 162-322-95
저항도
54 μΩ-cm
크기 × 두께
35 x 47 mm × 0.5 mm
bp
3464 °C (lit.)
mp
920 °C (lit.)
density
6.19 g/mL at 25 °C (lit.)
SMILES string
[La]
InChI
1S/La
InChI key
FZLIPJUXYLNCLC-UHFFFAOYSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
For updated SDS information please visit www.goodfellow.com.
법적 정보
Product of Goodfellow
Storage Class Code
4.3 - Hazardous materials which set free flammable gases upon contact with water
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
Stephen J P Damment et al.
Clinical pharmacokinetics, 47(9), 553-563 (2008-08-14)
Lanthanum carbonate is considered to be the most potent of a new generation of noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease (CKD), a condition associated with progressive bone and cardiovascular pathology and a markedly elevated risk
Marc E De Broe
Seminars in dialysis, 21(2), 142-144 (2008-02-06)
The recent recognition of gadolinium (Gd) administration as a cause of nephrogenic systemic fibrosis (NSF) is a growing concern. The similarity of Gd and lanthanum (La), based on their place in the table of Mendeljev, has led to assumptions that
Mario Cozzolino et al.
Expert opinion on pharmacotherapy, 13(16), 2337-2353 (2012-10-05)
High phosphate levels are associated with unfavorable outcomes in ESRD. Recent data suggested that phosphate levels within the normal range are equally associated with poor outcomes in the community and CKD stage 3 - 4. Several concept papers support the
Declan de Freitas et al.
Seminars in dialysis, 20(4), 325-328 (2007-07-20)
Hyperphosphatemia is associated with increased morbidity and mortality in dialysis patients. Oral phosphate binders are necessary to control serum phosphate in patients eating a normal diet and undergoing peritoneal dialysis or thrice weekly hemodialysis. Until recently, none of the available
Amy Barton Pai et al.
Expert opinion on drug metabolism & toxicology, 5(1), 71-81 (2009-02-25)
Hyperphosphatemia is recognized as a principal mineral disorder in chronic kidney disease (CKD) that leads to the development of secondary hyperparathyroidism. Recent data indicate that hyperphosphatemia is associated with accelerated cardiac calcification and increased mortality in patients with CKD. Control
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
